ABSTRACT
BACKGROUND: Extracorporeal photopheresis (ECP) as a part of multimodality therapy, is one of the treatments for Sézary syndrome (SS) and advanced stage mycosis fungoides (MF). This study aims to describe cutaneous and peripheral blood responses of patients with MF and SS who received multimodality therapy. METHODS: In this cross-sectional retrospective study, patients with MF or SS who received ECP treatment in combination with at least one additional systemic treatment between 2011 and 2018 were included. ECP consisted of a two-session cycle every 2 to 4 weeks. Cutaneous and blood responses were evaluated with updated criteria. RESULTS: Twenty-eight patients (11 (39%) with MF and 17 (51%) with SS) were included. Their median age at diagnosis was 63 (57-67) years. The median number of treatments before ECP was 2 (1-3). Seven out of 11 patients with MF (63%) underwent an assessment of cutaneous response. Five patients (70%) presented a partial response; 1 (15%), stable disease, and 1 (15%) progressive disease. Thirteen of the 17 patients with SS (76%) underwent evaluation. One patient (8%) presented a complete cutaneous response; 6 (46%), a partial response; 5 (38%), stable disease; and 1 (8%), progressive disease. None of them relapsed during the study period in both groups. No ECP-related adverse effects occurred during the study. CONCLUSION: Most patients with SS and MF who underwent multimodality therapy with ECP had favorable cutaneous and blood response. It is safe to combine ECP with other treatments. Studies with large numbers of patients are necessary to assess the effects of ECP on patient survival.
Subject(s)
Lymphoma, T-Cell, Cutaneous/therapy , Photopheresis/methods , Aged , Argentina , Combined Modality Therapy , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Mycosis Fungoides/therapy , Retrospective Studies , Sezary Syndrome/therapy , Skin Neoplasms/therapy , Treatment OutcomeABSTRACT
O câncer de ovário é a terceira neoplasia ginecológica mais incidente no Brasil com alta letalidade. Seu tratamento é sempre multidisciplinar envolvendo cirurgia e quimioterapia. No SEONC-HC-UFU realizamos quimioterapia baseada em platina e taxanos, tanto em neoadjuvância (pacientes com cirurgia não oncológica) como em adjuvância (pacientes com ressecção oncológica). Pacientes em tratamento sem intuito curativo recebem o mesmo esquema terapêutico caso nunca tenham sido tratados ou se foram há mais de seis meses. Pacientes resistentes a platina recebem, enquanto apresentarem performance, tratamento de segunda linha com gencitabina ou hormonioterapia (tamoxifeno). Após falha na segunda linha, pacientes recebem ?best supportive care? no ambulatório de cuidados paliativos. O seguimento e avaliação de respostas das pacientes são realizados através da dosagem periódica do marcador tumoral CA 125 e imagem quando indicada.